Binex Cefradine Injection

Adult administration

Adults: Administer 2～4g (potency) of cefradine hydrate per day in 4 divided doses by intravenous or intramuscular injection. For bone infections, administer 1g (potency) per dose intravenously 4 times daily. For uncomplicated pneumonia, skin and skin-structure infections, and most other infections, administer 500mg (potency) per dose intravenously or intramuscularly 4 times daily. For severe infections (e.g., sepsis), the dose may be increased to 8g (potency) per day. Patients with renal impairment: Administer by intravenous or intramuscular injection according to the following creatinine clearance (mL/min/1.73㎡). The initial dose is 750mg (potency), and the maintenance dose is 500mg (potency), administered as follows. Creatinine clearance (mL/min) >20: dosing interval (hours) 6～12 Creatinine clearance (mL/min) 15～20: dosing interval (hours) 12～24 Creatinine clearance (mL/min) 10～14: dosing interval (hours) 24～40 Creatinine clearance (mL/min) 5～9: dosing interval (hours) 40～50 Creatinine clearance (mL/min) <5: dosing interval (hours) 50～70 Adjust the dose appropriately according to age and symptoms. As with other antibiotics, treatment should generally continue for at least 48～72 hours after symptoms have resolved or there is evidence that the bacteria have been eradicated. For group A beta-hemolytic streptococcal infections, treatment for at least 10 days is recommended to prevent the risk of rheumatic fever or glomerulonephritis.

Child administration

Children: 50～100mg (potency) per kg of body weight per day may be administered by intravenous or intramuscular injection in 4 divided doses, but the adult dose must not be exceeded.

This drug should not be administered to patients who have previously experienced shock due to this drug. It is also advisable not to use this drug in patients with a history of myocardial infarction. Principally, this drug should not be given to patients who have had allergies to this drug or cephalosporins, but in unavoidable cases, it must be used very cautiously. Patients allergic to penicillin antibiotics should also be administered with caution. Patients with a tendency to experience allergic reactions such as bronchial asthma, skin rash, or hives should also be careful. Severely impaired renal function patients should take special precautions when using this drug. Patients who cannot eat well or receive parenteral nutrition, older patients, or those in poor general condition may show symptoms of vitamin K deficiency, so their condition should be closely monitored. Patients with a history of myocardial infarction also require caution. This drug can cause shock, so the patient's condition should be closely observed during administration. If symptoms such as dizziness, sweating, or oral discomfort appear, administration should be immediately stopped and appropriate treatment should be given. If allergic reactions such as rash, hives, or swelling occur, administration should be halted and treatment sought. Gastrointestinal side effects can rarely cause severe colitis, and if abdominal pain or diarrhea occurs, administration should be stopped immediately. Symptoms such as nausea, vomiting, heartburn, and loss of appetite may also occur. In the respiratory system, symptoms such as pneumonia or eosinophilia can rarely occur, so if there is shortness of breath or cough, administration should be stopped and treatment given. Laboratory tests may show granulocytopenia, anemia, or thrombocytopenia, therefore regular check-ups are necessary. Severe skin reactions such as severe rashes or Stevens-Johnson syndrome may rarely occur. Liver function abnormalities or hepatitis symptoms may appear, so the liver condition should be regularly checked. Renal function may deteriorate rapidly, so regular kidney function tests should be performed and administration should be stopped if there are any abnormal signs. This drug can cause dysbiosis and vitamin K deficiency leading to bleeding tendencies, so caution is needed. Headaches or general malaise, discomfort in the upper abdomen, and other symptoms have also been rarely reported. To prevent the emergence of resistant bacteria, it is advisable to check the sensitivity of the infective microorganism and administer for only the minimum necessary duration. To prevent shock reactions, it is recommended to conduct patient history and skin reaction tests before administration. During administration, it is important to prepare for emergencies and monitor patients in a stable condition adequately. Caution should be taken when using this drug in combination with diuretics or aminoglycoside antibiotics as it may burden the kidneys. During pregnancy, as safety has not been sufficiently established, this drug can only be administered when the benefit outweighs the risk. Women who are breastfeeding should be cautious as the drug can be transmitted through breast milk. Safety has not been established in preterm infants and newborns, and it is advisable not to administer it to infants under 9 months of age. In elderly patients, with reduced physical function, adverse reactions may occur more easily, so the dosage and interval should be adjusted, and their condition should be closely monitored. The risk of bleeding due to vitamin K deficiency is also elevated, necessitating caution. Some clinical tests may be affected by this drug, so care should be taken when interpreting test results. Transient pain at the injection site may occur, and thrombophlebitis can happen with intravenous administration, requiring caution. In the case of subcutaneous injection, sterile abscesses may form, so deep intramuscular injection is recommended.

Shock

This drug should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius. Storing it this way can help maintain its efficacy for a longer period.

Appearance

A white to yellowish white crystalline powder in a brown vial injection

Package unit

Company packaging unit